Aristotle University Of Thessaloniki (AUTH)
In vivo και ex vivo γονιδιακή θεραπεία της θαλασσαιμίας με χρήση ενός αδενο-ιικού φορέα γ-σφαιρίνης
Abstract
dc:descriptionTo overcome the cost and complexity of the current thalassemia ex vivo gene therapy protocols, we developed a minimally invasive and readily translatable approach for in vivo HSC gene delivery which abrogates the need for HSC leukapheresis, CD34+ cell selection, ex vivo HSC culture, myeloablation and ultimately, transplantation. Our approach involves HSC mobilization with G-CSF/AMD3100 and intravenous injections of a hybrid vector system consisting of a CD46-targeting, helper-dependent adenoviral vector, and the hyperactive Sleeping Beauty transposase (SB100x) that mediates integration of the vector-encoded γ-globin and mgmtP140K genes. Transduced HSCs home back to the bone marrow where they persist long-term. We tested our approach in a mouse model recapitulating the phenotype of human β-thalassemia intermedia (CD46+/+/Hbbth-3 mice). At week 8 post in vivo transduction, a 4-dose O6BG/BCNU treatment was administered in order to in vivo select for gene corrected hematopoietic progenitors, thus recovering the HbF expression in 76.0±5.7% of the circulating erythrocytes, by week 29 post in vivo transduction. Hematological parameters at week 29 post in vivo transduction, were significantly improved over baseline or were indistinguishable from normal values, suggesting near to complete phenotypic correction. Treated mice showed significant reduction of spleen size, extramedullary erythropoiesis and parenchymal hemosiderosis. Safety was demonstrated by the good tolerability of treatment, the absence of alterations in hematopoiesis, the normal colony-forming potential of bone marrow cells and the random integration pattern of our vector system. Elevated production of fetal hemoglobin (HbF) throughout adult life, a benign condition known as Hereditary Persistence of Fetal Hemoglobin (HPFH), has been shown to ameliorate the clinical phenotype of β-thalassemia. Recently, genome editing approaches led to new therapeutic opportunities, enabling specific reactivation of HbF. Here, we developed a helper-dependent adenoviral (HDAd5/35++) vector, tropic to HSCs via CD46, to reactivate the expression of γ-globin by in vivo gene editing of mobilized HSCs, using a CRISPR/Cas9 system to simultaneously disrupt both the binding sites of the gamma globin suppressor BCL11A within HBG1 and HBG2 promoters and the erythroid BCL11A enhancer (HDAd-CRISPR-Dual). To test our hypothesis, for the first time, we generated a xenografted thalassemic mouse model, by transplanting to NBSGW mice CD34+ cells from thalassemic patients to establish human thalassemic hemopoiesis. Six weeks post transplantation, HSPCs from the chimeric murine bone marrow were successfully mobilized to the periphery by administration of G-CSF (250μg/kg for 6 days) and Plerixafor (50μg/kg for 4 days). Forty minutes after the last dose of plerixafor the mice were intravenously injected with the HDAd-CRISPR-Dual vector allowing selective transduction of the human HSCs, as CD46 is not expressed on mouse HSCs. No cytotoxic effects were observed in CD34+ thalassemic cells post ex vivo or in vivo dual editing by HDAd-CRISPR-Dual vector. Importantly, dual-editing led to significantly enhanced HbF-expressing erythroid cells both in vitro and in vivo, which resulted in an improved erythroid lineage maturation profile in vivo, reduced ROS levels and reduced spleen size. Finally, no chromosomal rearrangements were detected by G-banding karyotyping in double-edited cells during erythroid differentiation, indicating that large genomic translocations did not occur between the two edited sites. Overall, we present a simplified platform for gene therapy of thalassemia, which can serve as a cost-efficient and “portable” approach to make gene therapy accessible even to resource-poor regions where thalassemia major is endemic but only minimally complex strategies could be adopted.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Georgakopoulou, Afroditi
- Γεωργακοπούλου, Αφροδίτη
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51997